Details:

Corporate Authors:
Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ; Tennessee.‏ ‎Department of Public Health‏.
Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ; Tennessee.‏ ‎Department of Public Health‏. Less -
Description:
October 26, 2012, 18:00 ET (6:00 PM ET)

CDCHAN-00331-2012-26-10-UPD-N

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are working with the Tennessee Department of Health (TDH) on investigating a cluster of at least 12 patients with thrombotic thrombocytopenic purpura (TTP) who have injected the opioid pain reliever, Opana ER® (oxymorphone extended-release), for nonmedical reasons since February, 2012. Investigation is ongoing.

This HAN notice provides information on the following:

• Status of the investigation

• Background on T T P and Opana ER®

• Recommendations

• Case definition


Subject:
[+]
Analgesics, Opioid/adverse Effects
Case-Control StudiesDelayed-Action Preparations
Disease Outbreaks
Oxymorphone/adverse Effects
Purpura, Thrombotic Thrombocytopenic/chemically Induced
Sepsis/chemically Induced
Substance Abuse, Intravenous/complications

Series:
HAN ; 331
Document Type:
HAN Health Advisory
Place as Subject:
Tennessee
Collection(s):
Health Alert Network (HAN)
Main Document Checksum:
[+]
urn:sha256:a4e2c8c4070d46f8e34431618d2b9e4c0ea52366288bc18c20d74d43d2eb1a01
File Type:

Supporting Files

• No Additional Files

More +